The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme
DA Chistiakov, IV Chekhonin, VP Chekhonin - European journal of …, 2017 - Elsevier
In epithelial tumors, the epidermal growth factor receptor (EGFR) controls key signaling
pathways responsible for growth, proliferation, migration, and survival of tumor cells. The …
pathways responsible for growth, proliferation, migration, and survival of tumor cells. The …
Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma
J Tang, N Huang, X Zhang, T Zhou, Y Tan… - International journal …, 2017 - Taylor & Francis
The extent of resection is a significant prognostic factor in glioma patients. However, the
maximum safe resection level is difficult to determine due to the inherent infiltrative character …
maximum safe resection level is difficult to determine due to the inherent infiltrative character …
A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants
H Guan, Y Du, Y Ning, X Cao - Future Medicinal Chemistry, 2017 - Taylor & Francis
The EGFR is one of the most popular targets for anticancer therapies and many drugs, such
as erlotinib and gefitinib, have got enormous success in clinical treatments of cancer in past …
as erlotinib and gefitinib, have got enormous success in clinical treatments of cancer in past …
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
S Ghosh, G Sharma, J Travers, S Kumar, J Choi… - Molecular cancer …, 2019 - AACR
Progressive upregulation of checkpoints on tumor-infiltrating lymphocytes promotes an
immunosuppressive tumor microenvironment, severely compromising tumor immunity …
immunosuppressive tumor microenvironment, severely compromising tumor immunity …
[HTML][HTML] The effect of and mechanism underlying autophagy in hepatocellular carcinoma induced by CH12, a monoclonal antibody directed against epidermal growth …
Background/Aims: Epidermal growth factor receptor variant III (EGFRvIII), the most frequent
EGFR variant, is constitutively activated without binding to EGF and is correlated with a poor …
EGFR variant, is constitutively activated without binding to EGF and is correlated with a poor …
Canis lupus familiaris as relevant animal model for breast cancer-a comparative oncology review.
L Raduly, R Cojocneanu-Petric… - … Science Papers & …, 2018 - search.ebscohost.com
Comparative oncology represents an important tool in cancer research and drug
development. After the sequencing of the canine genome, many similarities between canine …
development. After the sequencing of the canine genome, many similarities between canine …
Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models
P Gonzalez-Alonso, I Cristobal, S Zazo… - Current Medicinal …, 2018 - ingentaconnect.com
Background: Overexpression and amplification of the human epidermal growth factor
receptor 2 (HER2) occur in 20% of total breast carcinomas. HER2-overexpression is …
receptor 2 (HER2) occur in 20% of total breast carcinomas. HER2-overexpression is …
[PDF][PDF] Trastuzumab mAb-based ELISA Assay Kit
P Insert - eaglebio.com
The drug Trastuzumab (trade names Herceptin®, Herclone®) is a recombinant DNA-derived
humanized monoclonal antibody that selectively targets the extracellular domain of the …
humanized monoclonal antibody that selectively targets the extracellular domain of the …
[PDF][PDF] Przeciwciała monoklonalne w regulacji transdukcji sygnału receptora naskórkowego czynnika wzrostu (EGFR) w komórkach nowotworowych
RP Kampa, D Sypniewski… - Annales Academiae …, 2018 - bibliotekanauki.pl
Receptor naskórkowego czynnika wzrostu EGFR (Epidermal Growth Factor Receptor), ze
względu na jego ważny udział w patogenezie nowotworów złośliwych, jest obiektem …
względu na jego ważny udział w patogenezie nowotworów złośliwych, jest obiektem …